Health care giant Johnson & Johnson (NYSE:JNJ) made its 1st acquisition in China this week, picking up Guangzhou Bioseal Biotech for an undisclosed amount.
J&J has been doing business in China for more than 25 years, including last year’s launch of a medical device and diagnostics innovation center there.
"This transaction reinforces our commitment to China and delivering innovative medical device solutions to the Chinese market," J&J’s Chinese medical president Xie Wen Jian said in prepared remarks. "We are very pleased to add the Bioseal brand to our growing portfolio of hemostasis products in China and we look forward to working with our new Bioseal colleagues to bring their innovative products to more physicians and patients."
Bioseal developed a sealant used to control bleeding during surgery, the only porcine plasma-derived fibrin sealant approved for use in China, according to a press release.
The newly acquired company will work alongside J&J’s Ethicon subsidiary, which already markets its Surgical and Surgiflow biosurgery products in China.
Aethlon expects $1.4M in full-year revenues
Aethlon Medical (OTC:AEMD), which last year notched its 1st-ever revenues with a $6.8 million contract with the Defense Advanced Research Projects Agency, advised investors that it expects to post $1.4 million in revenue for its March 31, 2012 fiscal year end. Read more
Washington group pushes women’s pelvic health
Personal Medical Corp., a Redmond, Wash.-based medical device maker dedicated to advancing women’s pelvic health, announced its official launch this week. The company was previously a wholly owned subsidiary of SRS Medical in Billerica, Mass., whose founder and former CEO Kevin Connolly will take the helm at Personal Medical.
Personal Medical’s portfolio includes the inFlow device, which it touts as the 1st technology solution for women with neurogenic underactive bladder, as well as the Restore Continence suite of devices for treating of urinary incontinence and prolapse. Read more
Invest in R&D, survey says
Although many industries boost shareholder value by reinvesting in the company, but device makers may do well to put their money toward research & development, an analysis by CFO.com. The group noted that in its analysis of the 30 largest publicly traded U.S. med-tech companies, those that reinvested in R&D outperformed their peers by 11% in terms of total shareholder return. Read more
GPOs: Novation signs pulse oximetry deals with Masimo, Nonin Medical
Masimo (NSDQ:MASI) signed a 3-year deal to supply SET and Rainbow SET pulse oximetry systems to members of Novation. The group purchasing organization also signed a pulse oximetry deal with Nonin Medical. Read more
Funding Roundup
- Infection control systems maker Nanosonics looks to raise $12M at 53¢ per share
- Image Stream Medical raises $600k in equity from 3 investors
Analysts’ ups and downs
- Allergan (NYSE:AGN): Jeffries raises price target to $95, maintains "hold" rating
- AthenaHealth (NSDQ:ATHN): Morgan Stanley upgrades to "equal-weight" rating
- AtriCure (NSDQ:ATRC): Leerink Swann maintains "outperform" rating, $14 price target
- Edwards Lifesciences (NYSE:EW): Cannacord Genuity maintains "positive" rating
- LeMaitre Vascular (NSDQ:LMAT): Cannacord Genuity lowers price target from $7.50 to $7, maintains "buy" rating
- Smith & Nephew (FTSE:SN): Numis upgrades to "buy" rating, maintains 740p price target
- Staar Surgical Co. (NSDQ:STAA): Cannacord Genuity lowers price target from $14.50 to $14, maintains "buy" rating
- Teleflex (NYSE:TFX): Jeffries maintains "hold" rating, ups price target from $60 to $64
- Volcano (NSDQ:VOLC): Leerink Swann maintains "outperform" rating, $33 price target
- Wright Medical (NSDQ:WMGI): Leerink Swann maintains "market perform" rating, ups price target from $19 to $20
